<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01139021</url>
  </required_header>
  <id_info>
    <org_study_id>V72P13E2</org_study_id>
    <secondary_id>EudraCT No 2009-018101-52</secondary_id>
    <nct_id>NCT01139021</nct_id>
  </id_info>
  <brief_title>One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age</brief_title>
  <official_title>A Phase 3, Open-Label, Multi-Center, Extension Study of V72P13E1 to Assess Antibody Persistence at One Year After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting at 12 Months of Age and to Evaluate the Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One year antibody persistence after the fourth dose boost or two catch-up doses administered
      starting from 12 months of age and to evaluate the response to a a third dose boost or two
      catch-up dose starting at 24 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>12 months post booster (fourth) vaccination.</time_frame>
    <description>To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>12 months post booster (fourth) vaccination.</time_frame>
    <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on MITT population (Primary).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>12 months post booster (fourth) vaccination.</time_frame>
    <description>To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953.
Analysis was done on MITT population (Primary).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>12 months post two catch-up dose vaccination and 6 months post booster dose.</time_frame>
    <description>To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>6month post booster dose and 12 months post two catch-up dose vaccination.</time_frame>
    <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.</measure>
    <time_frame>1 month post booster dose versus prebooster.</time_frame>
    <description>To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.</measure>
    <time_frame>12 months post two catch-up dose vaccination and 6 months post booster dose.</time_frame>
    <description>To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</measure>
    <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
    <description>To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</measure>
    <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
    <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</measure>
    <time_frame>1 month post two catch-up doses versus prevaccination</time_frame>
    <description>To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains.
Analysis was done on MITT population (Secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.</measure>
    <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
    <description>To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain.
Analysis was done on MITT population (Secondary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</measure>
    <time_frame>Up to 7 days after any vaccination.</time_frame>
    <description>To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</measure>
    <time_frame>Up to 7 days after any vaccination.</time_frame>
    <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</measure>
    <time_frame>Up to 7 days after any vaccination.</time_frame>
    <description>To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</measure>
    <time_frame>Up to 7 days after any vaccination</time_frame>
    <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>B246_12_M12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B246_12M13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B13_15_27</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B12_14_26</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B_24_26</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B12M13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject was randomized in group B13_15_27 but treated as group B12_M13.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rMenB+OMV NZ</intervention_name>
    <description>Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.</description>
    <arm_group_label>B246_12_M12</arm_group_label>
    <arm_group_label>B246_12M13</arm_group_label>
    <arm_group_label>B13_15_27</arm_group_label>
    <arm_group_label>B12_14_26</arm_group_label>
    <arm_group_label>B_24_26</arm_group_label>
    <arm_group_label>B12M13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female children, 23 to 27 months of age (naïve children)

          -  Available for all the visits scheduled in the study;

          -  For whom parent(s)/legal guardian(s) have given written informed consent according to
             local regulations after the nature of the study has been explained;

          -  Available for all the visits scheduled in the study;

          -  In good health as determined by medical history, physical examination, clinical
             judgment of the investigator.

          -  Healthy children who participated in the immunogenicity part of V72P13E1 and have
             received their last vaccination 12 months (-30/+60 days) before enrolment in V72P13E2;

          -  Who received all vaccinations with rMenB+OMV NZ in V72P13 and V72P13E1 according to
             the protocols;

          -  Who provided at least the blood sample one month after their fourth dose of rMenB+OMV
             NZ (groups B246_12M12/B246_12M13) or after their second dose of rMenB+OMV NZ (groups
             B13_15_27/B12_14_26) in V72P13E1 according to the protocol;

          -  For whom parent(s)/legal guardian(s) had given written informed consent after the
             nature of the study has been explained;

          -  In good health as determined by medical history, physical examination, clinical
             judgment of the investigator.

        Exclusion Criteria:

          -  Subjects whose parent(s)/legal guardian(s) were unwilling or unable to give written
             informed consent to participate in the study;

          -  History of any meningococcal B vaccine administration;

          -  Previous ascertained or suspected disease caused by N. meningitidis;

          -  For whom parent(s)/legal guardian(s) have given written informed consent according to
             local regulations after the nature of the study has been explained;

          -  History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component;

          -  Antibiotics treatment within 6 days prior to enrolment;

          -  Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis;

          -  Any serious chronic or progressive disease

          -  Known or suspected impairment/ alteration of the immune system,

          -  Receipt of, or intent to immunize with another vaccine, within 30 days prior and after
             vaccination with the investigational vaccines (within 14 days for licensed flu
             vaccines)

          -  Significant acute or chronic infection within the previous 7 days or axillary
             temperature ≥38C within the previous day;

          -  Family members and household members of research staff;

          -  Any serious chronic or progressive disease according to the judgment of the
             investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic
             disease, neurological disease or seizure, either associated with fever or as part of
             an underlying neurological disorder or syndrome, autoimmune disease, Human
             Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS),
             or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe
             malnutrition);

          -  Known or suspected impairment/alteration of the immune system, immunosuppressive
             therapy, use of systemic corticosteroids or chronic use of inhaled high-potency
             corticosteroids within 30 days prior to enrolment (use of low or moderate doses of
             inhaled steroids is not an exclusion);

          -  Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation within 90 days prior to enrolment;

          -  Participation in another clinical trial within 90 days prior to enrolment or planned
             for during study;

          -  Receipt of, or intent to immunize with any other vaccine(s) within 30 days prior to
             enrolment (exception: flu-vaccines should not be administered within 14 days prior to
             enrolment);

          -  Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Months</minimum_age>
    <maximum_age>27 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>amostatná ordinace praktického lékaře pro děti a dorost Jindřichův Hradec</name>
      <address>
        <city>Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dětské oddělení nemocnice Náchod</name>
      <address>
        <city>Náchod</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dětské oddělení nemocnice Pardubice</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tampere Medical School, Vaccine Research Center Tampere</name>
      <address>
        <city>Biokatu 10</city>
        <state>Tampere</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic,</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki East, Vaccine Research Clinic,</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South, Vaccine Research Clinic,</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Järvenpää, Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotka Vaccine Research Clinic</name>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio Vaccine Research Clinic</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahti Vaccine Research Clinic</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vantaa East, Vaccine Research Clinic</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vantaa West, Vaccine Research Clinic</name>
      <address>
        <city>Vantaa</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2010</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>April 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2015</results_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Meningococcal disease</keyword>
  <keyword>Prevention</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from Finland and Czech Republic study center.</recruitment_details>
      <pre_assignment_details>The eligible subjects from V72P13E1 (NCT00847145) who originally participated in the open-label, immunogenicity subset of parent study V72P13 (NCT00657709) and a naïve group, at 24 months of age, who did not previously participate in V72P13 (or V72P13E1) were enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B246_12M12</title>
          <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
        </group>
        <group group_id="P2">
          <title>B246_12M13</title>
          <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
        </group>
        <group group_id="P3">
          <title>B13_15_27</title>
          <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
        </group>
        <group group_id="P4">
          <title>B12_14_26</title>
          <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
        </group>
        <group group_id="P5">
          <title>B_24_26</title>
          <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        </group>
        <group group_id="P6">
          <title>B12M13</title>
          <description>Subject was randomized in group B13_15_27 but treated as group B12_M13.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="116"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="107"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>B246_12M12</title>
          <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
        </group>
        <group group_id="B2">
          <title>B246_12M13</title>
          <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
        </group>
        <group group_id="B3">
          <title>B13_15_27</title>
          <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
        </group>
        <group group_id="B4">
          <title>B12_14_26</title>
          <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
        </group>
        <group group_id="B5">
          <title>B_24_26</title>
          <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        </group>
        <group group_id="B6">
          <title>B12M13</title>
          <description>Subject was randomized in group B13_15_27 but treated as group B12_M13.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="116"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="508"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="1.0"/>
                    <measurement group_id="B2" value="25.3" spread="0.9"/>
                    <measurement group_id="B3" value="27.3" spread="0.9"/>
                    <measurement group_id="B4" value="26.6" spread="1.2"/>
                    <measurement group_id="B5" value="24.7" spread="1.4"/>
                    <measurement group_id="B6" value="26" spread="0"/>
                    <measurement group_id="B7" value="25.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Number of Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).</description>
        <time_frame>12 months post booster (fourth) vaccination.</time_frame>
        <population>Analysis was done on Modified Intention-To-Treat (MITT) population (Primary).</population>
        <group_list>
          <group group_id="O1">
            <title>B246_12M12</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_12M13</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
          </group>
          <group group_id="O3">
            <title>B246_12Tot</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 12th or 13th month after primary vaccination at 2nd ,4th and 6th months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of human Serum Bactericidal Assay (hSBA) GMTs through antibody persistence at 12 months after a booster (fourth) dose of Novartis Meningococcal B Recombinant Vaccine (rMenB+OMV NZ) in groups that received a three-dose primary series at 2, 4,6 months of age. Group B246_12M12 received Measles, Mumps, Rubella, Varicella (MMRV) at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on Modified Intention-To-Treat (MITT) population- (Primary).</description>
          <population>Analysis was done on Modified Intention-To-Treat (MITT) population (Primary).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (N=147,152,299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.38" lower_limit="5.55" upper_limit="9.83"/>
                    <measurement group_id="O2" value="8.3" lower_limit="6.17" upper_limit="11"/>
                    <measurement group_id="O3" value="6.5" lower_limit="5.63" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N=147,151,298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="52" upper_limit="91"/>
                    <measurement group_id="O2" value="90" lower_limit="67" upper_limit="121"/>
                    <measurement group_id="O3" value="81" lower_limit="71" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" lower_limit="1.24" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.4" upper_limit="2.29"/>
                    <measurement group_id="O3" value="1.91" lower_limit="1.7" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N=143,148,291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" lower_limit="3.24" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.62" lower_limit="2.65" upper_limit="4.94"/>
                    <measurement group_id="O3" value="3.35" lower_limit="2.88" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on MITT population (Primary).</description>
        <time_frame>12 months post booster (fourth) vaccination.</time_frame>
        <population>Analysis was done on MITT population (Primary).</population>
        <group_list>
          <group group_id="O1">
            <title>B246_12M12</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_12M13</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age</description>
          </group>
          <group group_id="O3">
            <title>B246_12Tot</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 12th or 13th month after primary vaccination at 2nd ,4th and 6th months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at on 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody persistence at 12 months after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately).
Analysis was done on MITT population (Primary).</description>
          <population>Analysis was done on MITT population (Primary).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (hSBA ≥1:5) (N=147, 152, 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="51" upper_limit="68"/>
                    <measurement group_id="O2" value="64" lower_limit="56" upper_limit="71"/>
                    <measurement group_id="O3" value="62" lower_limit="56" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:5) (N=147, 151, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="95" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O2" value="17" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O3" value="17" lower_limit="13" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:5) (N=143, 148, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="32" upper_limit="48"/>
                    <measurement group_id="O2" value="32" lower_limit="25" upper_limit="41"/>
                    <measurement group_id="O3" value="36" lower_limit="31" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:8) (N=147, 152, 299)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="35" upper_limit="52"/>
                    <measurement group_id="O2" value="47" lower_limit="39" upper_limit="55"/>
                    <measurement group_id="O3" value="45" lower_limit="39" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:8) (N=147, 151, 298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="94" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:8) (N=147, 153, 300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7" upper_limit="19"/>
                    <measurement group_id="O2" value="14" lower_limit="9" upper_limit="21"/>
                    <measurement group_id="O3" value="13" lower_limit="10" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:8) (N=143, 148, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="39"/>
                    <measurement group_id="O2" value="24" lower_limit="17" upper_limit="31"/>
                    <measurement group_id="O3" value="27" lower_limit="22" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953.
Analysis was done on MITT population (Primary).</description>
        <time_frame>12 months post booster (fourth) vaccination.</time_frame>
        <population>Analysis was done on MITT population (Primary).</population>
        <group_list>
          <group group_id="O1">
            <title>B246_12M12</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
          </group>
          <group group_id="O2">
            <title>B246_12M13</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.</description>
          </group>
          <group group_id="O3">
            <title>B246_12Tot</title>
            <description>Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 12th or 13th month after primary vaccination at 2nd ,4th and 6th months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) to Assess Antibody Persistence at One Year After a Booster Dose of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of GMCs determined by Enzyme Linked Immunosorbent Assay (ELISA) through antibody persistence at one year after a booster (fourth) dose of rMenB+OMV NZ in groups that received a three-dose primary series at 2, 4, 6 months of age. Group B246_12M12 received MMRV at 12 months of age (concomitantly) and group B246_12M13 received MMRV at 13 months of age (separately) against vaccine antigen 287-953.
Analysis was done on MITT population (Primary).</description>
          <population>Analysis was done on MITT population (Primary).</population>
          <units>Concentration IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="293" upper_limit="442"/>
                    <measurement group_id="O2" value="389" lower_limit="314" upper_limit="482"/>
                    <measurement group_id="O3" value="352" lower_limit="317" upper_limit="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
        <time_frame>12 months post two catch-up dose vaccination and 6 months post booster dose.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B12+B13Tot</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 13th and 15th months or 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27th or 26th months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs to Assess Antibody Persistence at 12 Months After Two Catch-up Doses and 6 Months After Booster Dose of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of hSBA GMTs at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (12months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="9.01" upper_limit="23"/>
                    <measurement group_id="O2" value="8.4" lower_limit="4.13" upper_limit="17"/>
                    <measurement group_id="O3" value="10" lower_limit="8" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="43" upper_limit="123"/>
                    <measurement group_id="O2" value="71" lower_limit="32" upper_limit="154"/>
                    <measurement group_id="O3" value="65" lower_limit="49" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="1.09" upper_limit="2.55"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.64" upper_limit="2.27"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.39" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (12months) (N= 64, 18, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" lower_limit="2.14" upper_limit="6.54"/>
                    <measurement group_id="O2" value="3.29" lower_limit="1.43" upper_limit="7.56"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.5" upper_limit="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="41" upper_limit="113"/>
                    <measurement group_id="O2" value="70" lower_limit="32" upper_limit="151"/>
                    <measurement group_id="O3" value="51" lower_limit="38" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" lower_limit="332" upper_limit="827"/>
                    <measurement group_id="O2" value="525" lower_limit="263" upper_limit="1047"/>
                    <measurement group_id="O3" value="518" lower_limit="405" upper_limit="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" lower_limit="5.23" upper_limit="15"/>
                    <measurement group_id="O2" value="16" lower_limit="7.13" upper_limit="35"/>
                    <measurement group_id="O3" value="8.8" lower_limit="6.63" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (6months) (N= 66, 16, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="O2" value="36" lower_limit="17" upper_limit="78"/>
                    <measurement group_id="O3" value="26" lower_limit="20" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
        <time_frame>6month post booster dose and 12 months post two catch-up dose vaccination.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B12+B13Tot</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 13th and 15th months or 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27th or 26th months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Persistence at 12 Months After Two Catch up Doses and 6 Months After a Booster Doses of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (hSBA ≥1:5) (12months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="63" upper_limit="84"/>
                    <measurement group_id="O2" value="56" lower_limit="31" upper_limit="78"/>
                    <measurement group_id="O3" value="71" lower_limit="60" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:5) (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O3" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:5) (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="29"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O3" value="15" lower_limit="8" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:5) (12months) (N= 64, 18, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="27" upper_limit="52"/>
                    <measurement group_id="O2" value="28" lower_limit="10" upper_limit="53"/>
                    <measurement group_id="O3" value="37" lower_limit="26" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:5) (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:5) (6months) (N= 67, 18, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:5) (6months) (N= 67, 18, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="61" upper_limit="83"/>
                    <measurement group_id="O2" value="82" lower_limit="57" upper_limit="96"/>
                    <measurement group_id="O3" value="75" lower_limit="64" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:5) (6months) (N= 66, 16, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="83" upper_limit="97"/>
                    <measurement group_id="O2" value="94" lower_limit="70" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="85" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:8) (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="50" upper_limit="74"/>
                    <measurement group_id="O2" value="56" lower_limit="31" upper_limit="78"/>
                    <measurement group_id="O3" value="61" lower_limit="50" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:8) (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="87" upper_limit="99"/>
                    <measurement group_id="O2" value="94" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O3" value="95" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:8) (12months) (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="7" upper_limit="26"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="O3" value="13" lower_limit="7" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:8) (12months) (N= 64, 18, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="16" upper_limit="39"/>
                    <measurement group_id="O2" value="22" lower_limit="6" upper_limit="48"/>
                    <measurement group_id="O3" value="26" lower_limit="17" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:8) (6months) (N=67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="82" upper_limit="97"/>
                    <measurement group_id="O2" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O3" value="93" lower_limit="85" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:8) (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="71" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:8) (6months) (N= 67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="40" upper_limit="65"/>
                    <measurement group_id="O2" value="65" lower_limit="38" upper_limit="86"/>
                    <measurement group_id="O3" value="55" lower_limit="44" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:8) (6months) (N= 66, 16, 82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="76" upper_limit="94"/>
                    <measurement group_id="O2" value="81" lower_limit="54" upper_limit="96"/>
                    <measurement group_id="O3" value="85" lower_limit="76" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.</title>
        <description>To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.</description>
        <time_frame>1 month post booster dose versus prebooster.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B12+B13Tot</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 13th and 15th months or 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27th or 26th months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least Four Fold Increase in hSBA Titers to Evaluate Antibody Response 1 Month Post Booster Dose of rMenB+OMV NZ Vaccination.</title>
          <description>To assess the immunogenicity in terms of percentage of subjects with at least four fold increase in hSBA titers 1 month post booster dose of rMenB+OMV NZ administered at 26 or 27 months of age, in children previously administered two catch-up doses of rMenB+OMV NZ at either 12 and 14 or 13 and 15 months of age.Both the groups received MMRV at 12 months of age.</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (N= 66, 18, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="81" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N= 67, 18, 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="92" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="81" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N= 65, 18, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="94" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O3" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N= 62, 16, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="70" upper_limit="91"/>
                    <measurement group_id="O2" value="88" lower_limit="62" upper_limit="98"/>
                    <measurement group_id="O3" value="83" lower_limit="73" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.</title>
        <description>To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
        <time_frame>12 months post two catch-up dose vaccination and 6 months post booster dose.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.</description>
          </group>
          <group group_id="O3">
            <title>B12+B13Tot</title>
            <description>Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 13th and 15th months or 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27th or 26th months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMCs to Assess Antibody Persistence at One Year After Two Catch-up Doses and 6 Months After Booster of rMenB+OMV NZ Vaccination Against 287-953 Strain.</title>
          <description>To assess the immunogenicity in terms of GMCs determined by ELISA at 12 months after two catch up doses previously administered to children at either 12 and 14 or 13 and 15 months of age and 6 months after a booster dose of rMenB+OMV NZ administered at 26 or 27 months of age.
Both the groups received MMRV at 12 months of age.</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Concentration IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>287-953 (6months) (N=67, 17, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2314" lower_limit="1596" upper_limit="3355"/>
                    <measurement group_id="O2" value="3259" lower_limit="1859" upper_limit="5712"/>
                    <measurement group_id="O3" value="2597" lower_limit="2104" upper_limit="3205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>287-953 (12months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219" lower_limit="149" upper_limit="322"/>
                    <measurement group_id="O2" value="246" lower_limit="138" upper_limit="437"/>
                    <measurement group_id="O3" value="227" lower_limit="185" upper_limit="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
        <description>To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs to Characterize Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
          <description>To assess the immunogenicity in terms of GMTs through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (1months) (N= 105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" lower_limit="186" upper_limit="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (1months) (N= 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455" lower_limit="372" upper_limit="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (1months) (N=108 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="23" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (1months) (N=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="32" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (6months) (N=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="57" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (6 months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" lower_limit="1.57" upper_limit="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.04" lower_limit="6.39" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
        <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
        <population>Analysis was done on MITT population (Secondary)</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 and hSBA ≥1:8 to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
          <description>To assess the immunogenicity in terms of percentage of subjects with hSBA ≥1:5 and hSBA ≥1:8 through antibody response at at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          <population>Analysis was done on MITT population (Secondary)</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (hSBA ≥1:5) (1months) (N=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:5) (1months) (N= 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:5) (1months) (N= 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:5) (1months) (N= 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:5) (6months) (N=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="87" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:5) (6months) (N= 104 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:5) (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="11" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:5) (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="60" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:8) (1months) (N=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:8) (1months) (N= 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:8) (1months) (N= 108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:8) (1months) (N= 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H44/76-SL (hSBA ≥1:8) (6months) (N=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="80" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (hSBA ≥1:8) (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (hSBA ≥1:8) (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (hSBA ≥1:8) (6months) (N= 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="42" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
        <description>To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains.
Analysis was done on MITT population (Secondary).</description>
        <time_frame>1 month post two catch-up doses versus prevaccination</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Four Fold Increase in hSBA to Assess Antibody Response at 1 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
          <description>To assess the immunogenicity in terms of percentage of subjects with fourfold increases in hSBA titers at 1 month post two catch-up doses of rMenB+OMV NZ in children previously administered to naive children at 24 and 26 months of age against 4 strains.
Analysis was done on MITT population (Secondary).</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76-SL (N=105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 (N= 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 (N=108 )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M10713 (N= 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="76" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.</title>
        <description>To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain.
Analysis was done on MITT population (Secondary).</description>
        <time_frame>1 month and 6 months post two catch-up doses.</time_frame>
        <population>Analysis was done on MITT population (Secondary).</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>GMCs to Assess Antibody Response at 1 Month and 6 Month Post Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age Against 287-953 Strain.</title>
          <description>To assess the immunogenicity in terms of GMCs to assess through antibody response at 1 month and 6 month post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age against 287-953 strain.
Analysis was done on MITT population (Secondary).</description>
          <population>Analysis was done on MITT population (Secondary).</population>
          <units>Concentration IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>287-953 strain (1months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5448" lower_limit="4630" upper_limit="6411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>287-953 strain (6months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383" lower_limit="319" upper_limit="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</title>
        <description>To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
        <time_frame>Up to 7 days after any vaccination.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at 13 and 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at 12 and 14 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs) After Receiving a Booster (Third) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</title>
          <description>To assess the safety and tolerability by reporting solicited local and systemic AEs of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (N=67,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (N=)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits (N=67,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C )</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (&gt;= 40 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Attend. Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used Prev</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used Trt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</title>
        <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
        <time_frame>Up to 7 days after any vaccination.</time_frame>
        <population>The analysis was done on safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>B13_15_27</title>
            <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at 13 and 15 months of age.</description>
          </group>
          <group group_id="O2">
            <title>B12_14_26</title>
            <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at 12 and 14 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving a Booster (3rd) Dose of rMenB+OMV NZ Administered at One Year After Two Catch-up Doses of rMenB+OMV NZ, Previously Administered to Children.</title>
          <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events in yerms of serious adverse events (SAEs), atleast possibly related SAEs and AEs leading to withdrawl of a booster (third) dose of rMenB+OMV NZ administered at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 or 13 and 15 months of age in study V72P13E1.</description>
          <population>The analysis was done on safety subset.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
        <description>To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        <time_frame>Up to 7 days after any vaccination.</time_frame>
        <population>The analysis was done on safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
          <description>To assess the safety and tolerability by reporting solicited local and systemic adverse events of two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          <population>The analysis was done on safety subset.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Eat. Habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( &gt;= 38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (&gt;= 40 C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medical Attend. Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used Prev</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antipyr. Med. Used Trt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
        <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.</description>
        <time_frame>Up to 7 days after any vaccination</time_frame>
        <population>The analysis was done on safety subset.</population>
        <group_list>
          <group group_id="O1">
            <title>B_24_26</title>
            <description>Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Catch-up Doses of rMenB+OMV NZ Administered to Naive Children at 24 and 26 Months of Age.</title>
          <description>To assess the safety and tolerability in terms of number of subjects reporting unsolicited adverse events after receiving two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age. The analysis was done on safety subset.</description>
          <population>The analysis was done on safety subset.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least possibly related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study (solicited and unsolicited from Day 1 to Day 209). Any solicited and unsolicited adverse events, unsolicited SAE, medically attended AEs, AEs leading to withdrawal from the study were collected from day 1 through day.</time_frame>
      <desc>Any solicited and unsolicited adverse events were reported up to day 7 post vaccination for group B13_15_27, B12_14_26 and B_24_26 . Since no vaccination was administered to group B246_12M12 and B246_12M13 and antibody persistence was explored at 12 months after the fourth dose rMenB+OMV NZ, the two group are excluded from the reporting AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>B13_15_27</title>
          <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at 13 and 15 months of age.</description>
        </group>
        <group group_id="E2">
          <title>B12_14_26</title>
          <description>Subjects assessed for safety and tolerability after receiving a booster (third) dose of rMenB+OMV NZ at one year after two catch-up doses of rMenB+OMV NZ, previously administered to children at either 12 and 14 months of age.</description>
        </group>
        <group group_id="E3">
          <title>B24_26</title>
          <description>Subjects assessed for safety and tolerability after two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia Respiratory Syncytial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Adenoidal Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Exanthema Subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Speech Disorder Developmental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

